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ABSTRACT
Background Cystic fibrosis (CF) is a life- threatening 
genetic disease, affecting around 10 500 people in the 
UK. Precision medicines have been developed to treat 
specific CF- gene mutations. The newest, elexacaftor/
tezacaftor/ivacaftor (ELEX/TEZ/IVA), has been found to 
be highly effective in randomised controlled trials (RCTs) 
and became available to a large proportion of UK CF 
patients in 2020. Understanding the potential health 
economic impacts of ELEX/TEZ/IVA is vital to planning 
service provision.
Methods We combined observational UK CF Registry 
data with RCT results to project the impact of ELEX/TEZ/
IVA on total days of intravenous (IV) antibiotic treatment 
at a population level. Registry data from 2015 to 2017 
were used to develop prediction models for IV days over 
a 1- year period using several predictors, and to estimate 
1- year population total IV days based on standards of 
care pre- ELEX/TEZ/IVA. We considered two approaches 
to imposing the impact of ELEX/TEZ/IVA on projected 
outcomes using effect estimates from RCTs: approach 
1 based on effect estimates on FEV1% and approach 2 
based on effect estimates on exacerbation rate.
Results ELEX/TEZ/IVA is expected to result in significant 
reductions in population- level requirements for IV 
antibiotics of 16.1% (~17 800 days) using approach 1 
and 43.6% (~39 500 days) using approach 2. The two 
approaches require different assumptions. Increased 
understanding of the mechanisms through which ELEX/
TEZ/IVA acts on these outcomes would enable further 
refinements to our projections.
Conclusions This work contributes to increased 
understanding of the changing healthcare needs of 
people with CF and illustrates how Registry data can 
be used in combination with RCT evidence to estimate 
population- level treatment impacts.
INTRODUCTION
In the UK, approximately 10 500 people have 
cystic fibrosis (CF), one of the most common 
life- threatening genetic diseases.1 In recent years, 
precision medicines called CF transmembrane 
conductance regulator (CFTR) modulators have 
been developed to treat people with CF (pwCF). 
They work through targeted effects on CFTR 
processing and function and are specific for certain 
CF- causing gene mutations. Online supplemental 
table 1 summarises the CFTR modulator treatments 
that have been developed and current access within 
the UK. The first CFTR modulator to be approved 
was ivacaftor in 2012. It treats pwCF with at least 
one copy of a gating mutation, representing <5% 
of the CF population. Combination treatments 
ivacaftor/lumacaftor (IVA/LUMAC) (‘Orkambi’) 
and tezacaftor/ivacaftor (TEZ/IVA) (‘Symkevi’) 
gained National Health Service (NHS) funding 
approval in autumn 2019 for a larger proportion 
of the population based on genotype. Elexacaftor/
tezacaftor/ivacaftor (ELEX/TEZ/IVA) (‘Kaftrio’ 
Key messages
What is the key question?
 ► The newest precision medicine for cystic fibrosis 
(CF), elexacaftor/tezacaftor/ivacaftor (ELEX/
TEZ/IVA), has been found to be highly effective 
in randomised controlled trials (RCTs) and is 
becoming available to a large proportion of UK 
CF patients in 2020: what will its impact be on 
population level requirements for intravenous 
antibiotics?
What is the bottom line?
 ► ELEX/TEZ/IVA is expected to result in a 
significant reduction in the total population 
requirement for intravenous antibiotics of 
between 16.1% (~17 800 days) and 43.6% 
(~39 500 days).
Why read on?
 ► Discover how we combined observational UK 
Cystic Fibrosis Registry data with RCT results to 
show how treatment effect estimates translate 
into population- level healthcare needs, by 
projecting the impact of introducing ELEX/
TEZ/IVA into the UK CF population on days of 
intravenous antibiotic treatment in hospital and 
at home.
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in Europe, ‘Trikafta’ in the USA) received marketing authori-
sation in Europe in 2020 and began to be made available for 
use across the UK from mid-2020. Randomised controlled trials 
(RCTs) show that ELEX/TEZ/IVA is a highly effective modu-
lator in patients with two copies of the F508del gene mutation 
or one copy plus another minimal function gene mutation. 
European licencing and commissioning guidance and approval 
for funding have expanded the range of pwCF in the UK able 
to access ELEX/TEZ/IVA to anyone over the age of 12 with at 
least a single copy of the F508 mutation and people carrying a 
single copy of a listed mutation shown to be responsive to in 
vitro treatment. Over 5800 pwCF in the UK are eligible for this 
treatment and uptake has been rapid.2
Based on RCT results, it is anticipated that introducing ELEX/
TEZ/IVA will significantly improve lung function, reduce pulmo-
nary exacerbations, intravenous (IV) antibiotic use and improve 
quality of life. Understanding these impacts on NHS practice, 
and in particular on hospital bed utilisation, is vital to planning 
service provision for the UK CF population versus the competing 
needs of the wider population given the ongoing challenges of 
COVID-19. As yet, the health economic impacts are unknown. 
In this study, we have used observational data from the UK CF 
Registry combined with RCT results to project the potential 
impact of ELEX/TEZ/IVA on reducing IV antibiotic treatment at 
the UK CF population level.
The study aims were (1) to develop a prediction model that 
can be used to estimate the number of days of IV antibiotics used 
by the UK CF population aged ≥12 years over a 1- year period 
while receiving current standards of care, and (2) to project the 
impact of introducing ELEX/TEZ/IVA on this outcome measure. 
We considered three outcomes: number of hospital bed days 
due to IV antibiotics (hospital- IV- days), number of days using 
IV antibiotics at home (home- IV- days) and their sum (combined- 
IV- days). For the first aim, we used UK CF Registry data from 
2015 to 2017 to develop prediction models, and applied these 
to the most recently available data on the UK CF population 
recorded in 2018 to obtain estimates of population totals of each 
outcome over 1 year, assuming the 2018 population is approxi-
mately representative of the current population. For our second 
aim, we combined the predicted outcomes with evidence from 
RCTs on the impact of ELEX/TEZ/IVA.
METHODS
Data
The UK CF Registry is a national, secure database sponsored and 
managed by the Cystic Fibrosis Trust.3 It records demographic 
and longitudinal health data on nearly all (>99%) pwCF in 
the UK, to date capturing over 12 000 individuals, making it a 
reliable resource for estimating population outcomes. Data are 
collected in a standardised way at annual visits and stored on a 
centralised database.
This study uses data from visits recorded from 2015 to 2018. 
We excluded visits at which individuals were aged <12 years and 
visits post- transplant. At each visit, the Registry records the start 
and end dates of IV antibiotic use episodes covering the period 
since the previous visit. These were used to calculate hospital- IV- 
days, home- IV- days and combined- IV- days for each individual in 
the year following visits in 2015, 2016 and 2017. Dates of IV 
antibiotic use between an individual’s last visit and date of death 
are not typically recorded.
We also used data on several covariates (see section on Predic-
tion model development and evaluation (step 1)).
Prediction model overview
The analysis involved the following steps, discussed in more 
detail below:
Step 1. Registry data from 2015 to 2017 were used to 
develop and evaluate prediction models for hospital- IV- days and 
home- IV- days over a 1- year period based on a set of predictors 
measured at the start of the period.
Step 2. The prediction models were applied to the 2018 
patient data to estimate hospital- IV- days and home- IV- days over 
the following 1- year period.
Figure 1 Overview of approaches to imposing the potential effect of TEZ/IVA and ELEX/TEZ/IVA on hospital- IV- days and home- IV- days. CFTR, CF 
transmembrane conductance regulator; ELEX, elexacaftor; IVA, ivacaftor; TEZ, tezacaftor.
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Step 3. Since the most recently available data from the UK CF 
Registry (2018) pre- dates the general availability of TEZ/IVA and 
IVA/LUMAC, we also used findings from RCTs to incorporate 
the potential impact of TEZ/IVA on our results. The majority 
of people aged ≥12 and eligible for IVA/LUMAC and TEZ/IVA 
are using TEZ/IVA. Evidence on treatment effects from RCTs 
of TEZ/IVA was used to impose the potential impact of TEZ/
IVA on hospital- IV- days and home- IV- days over 1 year following 
annual visits in 2018, for individuals in a genotype group that is 
now (since 2019) eligible to receive TEZ/IVA.
Step 4. Evidence on treatment effects from RCTs of ELEX/
TEZ/IVA was used to impose the impact of ELEX/TEZ/IVA on 
hospital- IV- days and home- IV- days over 1 year following annual 
visits in 2018, for individuals with genotypes such that they 
are eligible to receive this treatment, including those who have 
switched from TEZ/IVA to ELEX/TEZ/IVA.
Figure 1 provides a schematic overview of our analytical plan.
Prediction model development and evaluation (step 1)
Separate prediction models were fitted for the outcomes 
hospital- IV- days and home- IV- days using data on individuals 
observed at annual review visits in 2015, 2016 and 2017 and 
who did not die before their next visit. The outcomes are counts 
of days and many individuals have counts of zero. To account for 
this, the analysis uses a ‘hurdle’ model: a two- part model, where 
the first part is a logistic model for the probability of a zero, and 
the second part is a zero- truncated negative binomial model for 
positive counts. There are other peaks in the outcome distribu-
tions, particularly at multiples of 14 days, due to IV antibiotic 
prescribing practices (online supplemental figure 1), and we 
considered extended hurdle models allowing additional peaks 
but these did not provide improved predictions.
The models, which were fitted using combined data from 
2015 to 2017, are detailed in online supplemental section S1. 
Models included age, sex, and genotype and the following time- 
dependent predictors, which were measured at the start of each 
1- year period: FEV1% (obtained using Global Lung Function 
Initiative equations4) and body mass index obtained as single 
measures on the day of the annual visit, FEV1% measured at the 
previous visit, infection with Pseudomonas aeruginosa, Staphylo-
coccus aureus and Burkholderia cepacia (in the past year), diag-
nosis of CF- related diabetes, hospital- IV- days and home- IV- days 
over the past year. The included covariates were selected based 
on clinical consensus, and we aimed to include confounders of 
the associations between FEV1% and the outcomes, which was 
required for one of our approaches to imposing treatment effects 
in step 3 (approach 1, see below). Continuous and count covari-
ates were modelled using splines. Genotype was categorised into 
six groups reflecting eligibility for CFTR modulators (table 1). 
There were missing data in some time- dependent covariates. Due 
to the relatively low missingness (online supplemental table 3), 
we used the last- observation- carried- forward. There remained a 
minimal amount of missingness and individuals with remaining 
missing data were excluded. There was also some missingness 
in the outcome, including due to missing IV antibiotic episode 
dates between an individual’s last visit and his/her death. Indi-
viduals with missing outcome were excluded from the prediction 
model development. The predicted combined- IV- days was the 
sum of the predicted hospital- IV- days and home- IV- days.
The predictive performance of the model was evaluated using 
discrimination and calibration measures. Overfitting- corrected 
estimates of these measures were obtained using a bootstrapping 
approach.5 The model was fitted in each bootstrap sample and 
evaluated in the same sample (in- sample performance) and in the 
subset of individuals not in the bootstrap sample (out- of- sample 
performance). Assessment measures were obtained in- sample 
and out- of- sample, and results are based on means across 1000 
bootstrap samples. Discrimination was assessed on the part 
of the model that predicts whether an individual’s outcome is 
zero using the area under the receiver operating characteristic 
(ROC) curve. We assessed overall predictive performance and 
calibration through the bias and root mean squared error of the 
predicted counts. Model calibration was also assessed graph-
ically—we divided the predicted outcomes into 100 ordered 
groups of equal size (based on quantiles) and compared the mean 
observed outcome with the mean predicted outcome in each 
group. Calibration was a key consideration in this investigation 
because we used the model to obtain predicted counts in subsets 
of the population under different potential treatment effects.6
Estimation of population totals (step 2)
We used the prediction model fitted to the complete 2015–2017 
data to obtain predictions of hospital- IV- days, home- IV- days 
and combined- IV- days for each individual in the 2018 data, for 
which observed outcomes were not available. We present the 
population totals and population means for each outcome for 
the whole 2018 CF population and within groups defined by 
access to CFTR modulators. Estimates are accompanied by 95% 
prediction intervals (95% PIs) (online supplemental section S2).
Imposing the potential impact of TEZ/IVA and ELEX/TEZ/IVA 
using RCT results (steps 3 and 4)
There have been two phase III RCTs of TEZ/IVA and two of 
ELEX/TEZ/IVA in pwCF aged ≥12 years (online supplemental 
table 2).7–10 To impose the effects of TEZ/IVA, we used results 
from the study of Taylor- Cousar et al7 comparing TEZ/IVA with 
placebo in F508del homozygotes. The primary endpoint was 
increase in FEV1% at 24 weeks, and the increase in the TEZ/IVA 
group was 3.4 points of FEV1% (95% CI 2.7 to 4.0). Despite 
the modest impact on FEV1%, the rate ratio for the second 
outcome of number of pulmonary exacerbations at 24 weeks 
was 0.65 (95% CI 0.48 to 0.88). Middleton et al9 investigated 
the ELEX/TEZ/IVA impact in F508del heterozygotes with a 
minimal function mutation. The estimated increase in FEV1% 
at 4 weeks (primary outcome) in the ELEX/TEZ/IVA group was 
13.6 (95% CI 12.4 to 14.8). The rate ratio for exacerbations 
(leading to hospitalisation or treatment with IV antibiotics) up 
to 24 weeks (secondary outcome) was 0.37 (95% CI 0.25 to 
0.55). Heijerman et al10 investigated the ELEX/TEZ/IVA impact 
in F508del homozygotes, with TEZ/IVA as the comparator. The 
estimated increase in FEV1% at 4 weeks in the ELEX/TEZ/IVA 
group was 10.4 (95% CI 8.6 to 12.2).
We considered two approaches to imposing the impact of 
TEZ/IVA and ELEX/TEZ/IVA on the outcomes, which require 
different assumptions: approach 1—using RCT results on the 
impact of the treatments on FEV1%; approach 2—using RCT 
results on the impact of the treatments on pulmonary exacerba-
tion rate. Approach 1 assumes the treatment effect on hospital- 
IV- days and home- IV- days is mediated entirely through its 
effect on FEV1% (see figure 2). Under approach 2, we make the 
assumption that the rate ratio for the treatment effect on exac-
erbation rate can be applied directly to rates of hospital- IV- days 
and home- IV- days —that is, we assume approximate equivalence 
between exacerbations and requirement for IV antibiotics both 
in hospital and at home. The two approaches therefore provide 
complementary evidence and have different merits. Individuals 
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who were F508del homozygous or F508del heterozygous with 
a residual function mutation were considered eligible for TEZ/
IVA and were assumed to be using it. These individuals were also 
assumed eligible for ELEX/TEZ/IVA, alongside F508del indi-
viduals heterozygous for minimal function gene mutations, but 
excluding those eligible for ivacaftor.
Figure 1 details the two approaches. When imposing the treat-
ment effects from the RCTs, we accounted for the uncertainty 
in the effect estimates and we obtained 95% PIs for population 
total outcomes (see online supplemental section S2).
For approach 1, the expected impacts of TEZ/IVA and ELEX/
TEZ/IVA are imposed, in turn, on each eligible individual’s 
observed FEV1% value in the 2018 data, and the prediction 
Table 1 Descriptive statistics for covariates included in the prediction model and outcome variables, excluding individuals with missing data in 
covariates or the outcomes, by year
2015 (n=5929) 2016 (n=6075) 2017 (n=5963) 2018 (n=6407)
Covariates   
Age Median (IQR) 25.1 (19.0–53.5) 25.8 (19.0–54.1) 26.0 (19.3–55.1) 26.4 (19.5–
56.0)
Sex Male, n (%) 3263 (53.6%) 3369 (53.7%) 3442 (53.9%) 3435 (53.6%)
  Female, n (%) 2829 (46.4%) 2903 (46.3%) 2938 (46.1%) 2972 (46.4%)
FEV1% Median (IQR) 67.1 (47.6–84.7) 68.2 (48.0–84.8) 68.1 (47.8–85.4) 68.6 (47.7–
85.3)
FEV1% previous year Median (IQR) 69.0 (49.5–85.7) 69.5 (50.3–85.9) 70.0 (50.5–86.0) 70.2 (50.2–
86.3)
Body mass index Median (IQR) 21.7 (19.5–24.2) 21.8 (19.5–24.3) 21.8 (19.6–24.5) 21.8 (19.6–
24.4)
Pseudomonas aeruginosa No, n (%) 2446 (40.2%) 2817 (44.9%) 2930 (45.9%) 2916 (45.5%)
  Yes, n (%) 3646 (59.8%) 3455 (55.1%) 3450 (54.1%) 3491 (54.5%)
Staphylococcus aureus No, n (%) 3567 (58.6%) 3976 (63.4%) 3937 (61.7%) 3893 (60.8%)
  Yes, n (%) 2525 (41.4%) 2296 (36.6%) 2443 (38.3%) 2514 (39.2%)
Burkholderia cepacia No, n (%) 5790 (95.0%) 5956 (95.0%) 6083 (95.3%) 6101 (95.2%)
  Yes, n (%) 302 (5.0%) 316 (5.0%) 297 (4.7%) 306 (4.8%)
CF- related diabetes No, n (%) 3764 (61.8%) 3877 (61.8%) 3941 (61.8%) 4085 (63.8%)
  Yes, n (%) 2328 (38.2%) 2395 (38.2%) 2439 (38.2%) 2322 (36.2%)
Genotype F508del homozygous 3026 (49.7%) 3079 (49.1%) 3102 (48.6%) 3131 (48.9%)
  F508 + minimal 1095 (18.0%) 1118 (17.8%) 1112 (17.4%) 1115 (17.4%)
  F508 + residual 307 (5.0%) 321 (5.1%) 337 (5.3%) 350 (5.5%)
  F508 + other/unknown 523 (8.6%) 549 (8.8%) 564 (8.8%) 559 (8.7%)
  Any gating mutation or R117H 686 (11.3%) 721 (11.5%) 765 (12.0%) 762 (11.9%)
  Other/unknown 455 (7.5%) 484 (7.7%) 500 (7.8%) 490 (7.6%)
Hospital- IV- days, past year* Zero, n (%) 3029 (49.7%) 3830 (61.1%) 3801 (59.6%) 3755 (58.6%)
  Median of non- zeros (IQR) 25.0 (14.0,42.0) 15.0 (9.0,32.0) 14.0 (9.0,31.0) 15.0 (9.0,32.0)
Home- IV- days, past year* Zero, n (%) 3025 (49.7%) 4400 (70.2%) 4500 (70.5%) 4489 (70.1%)
  Median of non- zeros (IQR) 26.0 (14.0–43.0) 18.0 (13.0–33.0) 20.0 (13.0–34.0) 19.0 (13.0–
34.0)
Outcome variables   
Hospital- IV- days,*† Zero, n (%) 3564 (60.1%) 3571 (58.8%) 3407 (57.1%) –
  Median of non- zeros (IQR) 15.0 (9.0–33.0) 15.0 (9.0–33.0) 16.0 (10.0–33.0) –
Home- IV- days,*† Zero, n (%) 4079 (68.8%) 4218 (69.4%) 4100 (68.8%) –
  Median of non- zeros (IQR) 18.0 (13.0–34.0) 20.0 (13.0–34.0) 20.0 (13.0–35.0) –
*When the start and end dates for a given episode were the same, the number of days was counted as 1; otherwise, the number of days for that episode was counted as the 
difference between the start and end dates.
†These are the counts of hospital- IV- days and home- IV- days in the year following the annual review visit in 2015, 2016 and 2017. By contrast, ‘Hospital- IV- days, past year’ and 
‘Home- IV- days, past year’ are the counts in the year leading up to the annual review visit.
Figure 2 Directed acyclic graph showing assumed relationships 
between covariates and outcomes for approach 1. BMI, body mass 
index; CF, cystic fibrosis; IV, intravenous.





ber 28, 2021 at T














model is then used to obtain predicted outcomes using the modi-
fied FEV1% values. To impose the potential effect of TEZ/IVA 
and ELEX/TEZ/IVA on FEV1% in our population using the RCT 
results, the regression coefficient(s) for FEV1% in the prediction 
model should have an interpretation as an approximation of the 
causal effect of FEV1% on the outcome. The prediction model 
should therefore include FEV1% plus confounders of the asso-
ciation between FEV1% and the outcome. The set of predictors 
included in the model are all temporally prior to the FEV1% 
measure and were selected as potential confounders, as well as 
our expectation that they would be predictors of the outcomes 
(figure 2).
For approach 2, we used the prediction models to obtain 
predicted hospital- IV- days and home- IV- days for each individual 
and then reduced these by a percentage determined by the RCT 




Between 2015 and 2018, 7461 individuals aged ≥12 years had 
data recorded in the Registry at least once, after excluding indi-
viduals post- transplant. Prediction models were developed using 
data from 2015 to 2017. After exclusions due to missing data (see 
online supplemental table 3), among which 4% were excluded 
because they had missing outcome data due to death, prediction 
model development was based on 17 967 annual data records 
on 6731 individuals, whose characteristics are summarised in 
table 1. In the combined 2015–2017 data, 58.7% of hospital- IV- 
days outcomes are zero, 69% of home- IV- days are zero and 48% 
had no IV antibiotic days either at hospital or at home.
Model development and evaluation
Parameter estimates from the prediction models are shown 
in online supplemental table 4. Table 2 and figure 3 show the 
results from assessing the predictive performance. Discrimina-
tion was assessed on the part of the model that predicts whether 
an individual’s outcome is zero. The AUC was 0.81 for hospital- 
IV- days and 0.82 for home- IV- days, indicating reasonable 
performance at discriminating between individuals who have a 
zero and non- zero count (a value of 0.5 would indicate that the 
model performed no better than chance and a value of 1 would 
indicate perfect discrimination). The out- of- sample values were 
only slightly lower than the in- sample values. Looking at the 
overall model performance, bias was close to 0, and correspond-
ingly, the observed population totals were close to the predicted 
totals. The root mean squared errors were similar for the two 
outcomes and indicate a reasonably substantial amount of varia-
tion between the observed and predicted outcomes.11 Such vari-
ability is reflected in the prediction intervals when the model 
is applied to the 2018 data. Calibration plots (figure 3) show 
that the models are well calibrated, meaning that the observed 
outcomes are, on average, similar to the predicted outcomes.
Predicted population totals and the potential impact of TEZ/
IVA and ELEX/TEZ/IVA
The 2018 data include 6407 individuals aged ≥12 years. Of 
these individuals, 54.3% (n=3481) were eligible for both TEZ/
IVA and ELEX/TEZ/IVA, and a further 26.1% (n=1674) were 
only eligible for ELEX/TEZ/IVA according to the definition 
of eligibility used in this paper. Table 3 shows the predicted 
population totals for each outcome in the 1 year following the 
2018 visit and table 4 shows the predicted population means. 
Table 2 Model evaluation results based on averages over 1000 
bootstrap samples
In- sample Out- of- sample
Hospital- IV- days
  AUC for the 
probability of a zero 
count
0.809 (0.802 to 0.815) 0.807 (0.798 to 0.815)
  Bias (days) 0.089 (0.041 to 0.133) 0.078 (−0.447 to 0.650)
  RMSE (days) 17.13 (16.34 to 17.87) 17.18 (16.26 to 18.53)
  Observed total 
(days)
191 143 (185 875 to 196 754) 70 325 (67 495 to 73 321)
  Predicted total 
(days)
192 745 (187 173 to 198 218) 70 841 (68 249 to 73 514)
Home- IV- days
  AUC for the 
probability of a zero 
count
0.822 (0.815 to 0.828) 0.820 (0.811 to 0.828)
  Bias (days) 0.092 (0.038 to 0.151) 0.063 (–0.424 to 0.589)
  RMSE (days) 15.83 (14.51 to 17.85) 15.92 (14.40 to 19.78)
  Observed total 
(days)
149 940 (144 790 to 154 897) 55 215 (52 810 to 57 748)
  Predicted total 
(days)
151 585 (146 256 to 156 826) 55 627 (53 320 to 58 318)
The model fitted in each bootstrap sample was evaluated in- sample and out- of- 
sample. Estimated 95% CI are given in parentheses and were obtained using the 
2.5th and 97.5th percentiles across the 1000 bootstrap samples.
AUC, area under the curve; RMSE, root mean squared error.
Figure 3 Plots showing the mean observed outcome in groups 
defined by 100ths of the distribution of the predicted outcome, against 
the mean predicted outcome in each group. Each point was obtained as 
the average over 1000 bootstrap samples. The solid line is the lowess 
curve. The dashed line is the line of equality. IV, intravenous.
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Before imposing any treatment effects, the predicted population 
totals are 67 700 (95% PI 64 700 – 71 300) hospital- IV- days 
and 47 300 (95% PI 44 800 – 49 900) home- IV- days. When 
imposing the potential impact of TEZ/IVA and ELEX/TEZ/
IVA on the population totals, we obtained somewhat different 
results between approaches 1 and 2, with the population totals 
of hospital- IV- days, home- IV- days and combined- IV- days being 
considerably smaller using approach 2, thus suggesting a larger 
treatment effect.
Under approach 1 for hospital- IV- days, imposing the TEZ/IVA 
effect on eligible individuals indicated a 4.8% reduction (95% 
PI −1.2%–10.1%) in the population total (to 64 500 days (95% 
PI 61 300–67 700)), and imposing the ELEX/TEZ/IVA effect 
(including for those assumed to switch from TEZ/IVA) indi-
cated a further 20% reduction (95% PI 14.4%–25.2%) in the 
population total (to 51 600 days (95% PI 48 500–54 700)). The 
population total includes hospital- IV- days and home- IV- days for 
individuals for whom no treatment effects are applied as they are 
not eligible for TEZ/IVA or ELEX/TEZ/IVA. This 20% reduc-
tion in population total hospital- IV- days corresponds to a reduc-
tion in the predicted mean number of days over 1 year from 10.1 
days (95% PI 9.6–10.6) to 8.0 days (95% PI 7.6–8.5). For the 
subset of individuals eligible for ELEX/TEZ/IVA, we estimated a 
reduction in the total hospital- IV- days from 57 000 (95% PI 54 
000–60 100) to 44 000 (95% PI 41 000–47000) after initiating 
or switching to ELEX/TEZ/IVA, representing a 22.7% reduc-
tion (95% PI 16.7%–28.5%). Under approach 1, the treatment 
impacts are less for home- IV- days, reflecting a weaker associa-
tion between FEV1% and home- IV- days in the prediction model. 
Imposing the TEZ/IVA effect indicated a 2.5% reduction (95% 
PI −4.2%–8.3%) in the population total home- IV- days, and 
imposing the ELEX/TEZ/IVA effect a further 10.2% reduction 
(95% PI 2.0%–18.1%). This corresponds to a reduction in the 
mean home- IV- days from 7.2 days (95% PI 6.8–7.6) to 6.4 days 
(95% PI 6.1–6.9)).
Table 3 Estimated population totals for each outcome in 1 year following the 2018 visit, presented as N/1000 (95% prediction interval (95% PI)), 
and % reductions: with no treatment effects applied, with the effect of TEZ/IVA imposed and with the effect of ELEX/TEZ/IVA imposed
Eligibility group
No treatment effects With TEZ/IVA effect applied to eligible individuals
With ELEX/TEZ/IVA effect applied to 
eligible individuals, including those 
assumed to switch from TEZ/IVA
N/1000 (95% PI) N/1000 (95% PI) % reduction (95% PI) N/1000 (95% PI)
% reduction 
(95% PI)
(A) Using approach 1 for imposing treatment effects
Hospital- IV- days
  Full cohort* 67.7 (64.7, 71.3) 64.5 (61.3, 67.7) 4.8 (–1.2, 10.1) 51.6 (48.5, 54.7) 20.0 (14.3, 25.2)
  TEZ/IVA+ELEX/TEZ/IVA† 41.5 (39.1, 44.4) 38.3 (36.0, 40.8) 7.7 (0.5, 14.4) 30.3 (28.0, 32.7) 20.8 (13.5, 27.4)
  ELEX/TEZ/IVA‡ 60.2 (57.3, 63.6) 57.0 (54.0, 60.1) 5.3 (–0.8, 11.2) 44.0 (41.0, 47.0) 22.7 (16.7, 28.5)
Home- IV- days
  Full cohort 47.3 (44.8, 49.9) 46.1 (43.7, 48.9) 2.5 (–4.2, 8.3) 41.3 (38.9, 44.1) 10.2 (3.7, 16.4)
  TEZ/IVA+ELEX/TEZ/IVA 30.1 (28.2, 32.2) 29.0 (27.0, 31.3) 3.9 (–4.5, 11.7) 25.9 (24.1, 28.1) 10.2 (2.0, 18.1)
  ELEX/TEZ/IVA 42.7 (40.4, 45.1) 41.5 (39.1, 44.2) 2.7 (–4.5, 9.3) 36.7 (34.4, 39.3) 11.4 (4.3, 17.9)
Combined- IV- days
  Full cohort 115.0 (110.9, 119.5) 110.6 (106.7, 114.9) 3.8 (–0.4, 8.0) 92.8 (92.8, 92.8) 16.1 (13.0, 19.2)
  TEZ/IVA+ELEX/TEZ/IVA 71.7 (68.5, 75.2) 67.3 (64.1, 70.6) 6.1 (0.7, 11.4) 56.3 (56.3, 56.3) 16.4 (12.2, 20.3)
  ELEX/TEZ/IVA 102.9 (99.0, 107.3) 98.5 (94.9, 102.7) 4.3 (–0.4, 8.6) 80.7 (80.7, 80.7) 18.1 (14.9, 21.4)
(B) Using approach 2 for imposing treatment effects
Hospital- IV- days
  Full cohort* 67.7 (64.6, 71.2) 53.5 (50.9, 56.3) 21.0 (20.0, 21.9) 30.3 (28.7, 32.0) 43.4 (42.2, 44.6)
  TEZ/IVA+ELEX/TEZ/IVA† 41.5 (39.2, 44.3) 27.3 (25.7, 29.2) 34.3 (33.5, 35.1) 15.7 (14.7, 16.7) 42.6 (41.4, 43.6)
  ELEX/TEZ/IVA‡ 60.2 (57.1, 63.5) 46.0 (43.6, 48.6) 23.7 (22.7, 24.6) 22.7 (21.5, 24.0) 50.6 (49.7, 51.5)
Home- IV- days
  Full cohort 47.3 (44.9, 49.9) 36.9 (35.1, 39.1) 21.8 (20.8, 22.9) 20.7 (19.5, 22.0) 44.0 (42.6, 45.3)
  TEZ/IVA+ELEX/TEZ/IVA 30.1 (28.2, 32.2) 19.8 (18.4, 21.3) 34.3 (33.3, 35.2) 11.4 (10.6, 12.3) 42.6 (41.2, 43.8)
  ELEX/TEZ/IVA 42.7 (40.3, 45.2) 32.4 (30.5, 34.3) 24.2 (23.1, 25.2) 16.1 (15.2, 17.1) 50.2 (49.2, 51.3)
Combined- IV- days
  Full cohort 115.0 (111.0, 119.4) 90.5 (87.2, 94.0) 21.3 (20.6, 22.0) 51.0 (49.0, 53.1) 43.6 (42.7, 44.6)
  TEZ/IVA+ELEX/TEZ/IVA 71.7 (68.6, 75.1) 47.1 (45.0, 49.5) 34.3 (33.6, 34.9) 27.1 (25.8, 28.5) 42.6 (41.7, 43.5)
  ELEX/TEZ/IVA 102.9 (98.8, 107.3) 78.3 (75.2, 81.6) 23.9 (23.1, 24.6) 38.8 (37.3, 40.5) 50.4 (49.7, 51.1)
For the TEZ/IVA effect results, the % reduction is relative to the situation with no treatment effects. For the ELEX/TEZ/IVA results, the % reduction is relative to the TEZ/IVA results.
*The full cohort of N=6407 individuals.
†The subset eligible for both TEZ/IVA and ELEX/TEZ/IVA (n=3481).
‡The whole set of individuals eligible for ELEX/TEZ/IVA, including those assumed to switch from TEZ/IVA (n=5155).
ELEX, elexacaftor; IVA, ivacaftor; TEZ, tezacaftor.
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Under approach 2 for hospital- IV- days, imposing the TEZ/
IVA effect gave a 21% reduction (95% PI 20.0%–21.9%) in 
the population total hospital- IV- days (to 53 500 days (95% 
PI 50 900–56 300)), and imposing the ELEX/TEZ/IVA effect 
(including for those assumed to switch from TEZ/IVA) a further 
43.4% reduction (95% PI 42.2%–44.6%) (to 30 300 days (95% 
PI 28 700–32 000)). The latter corresponds to a reduction in 
mean hospital- IV- days from 8.4 days (95% PI 7.9–8.8) to 4.7 
days. Under approach 2, the reductions for home- IV- days are 
very similar.
Overall, our results suggest that introducing ELEX/TEZ/
IVA is expected to result in a reduction in the population total 
requirement for IV antibotics (combined- IV- days) of between 
16.1% (approach 1) and 43.6% (approach 2), over and above 
the impacts of TEZ/IVA. Reasons for differences in the predicted 
outcomes under the two approaches are discussed below.
Our primary aim has been to provide projections of popu-
lation totals, rather than individual- level predictions. However, 
to provide clinical context, we obtained predictions from the 
model for example (hypothetical) individuals under standard 
care pre- ELEX/TEZ/IVA and after imposing the RCT treatment 
effect estimates. Table 5 provides predicted number of hospital- 
IV- days and home- IV- days for example individuals.
DISCUSSION
With the recent agreement that the NHS in England, Scotland, 
Wales and Northern Ireland will fund ELEX/TEZ/IVA after 
receiving its European license, the CF community is looking 
towards future planning for the changing healthcare needs of 
pwCF. We developed novel approaches to anticipate the impact 
of ELEX/TEZ/IVA on health service utilisation in the form of IV 
antibiotic usage. We estimated how many days of IV antibiotic 
treatment in hospital and at home will be required by pwCF 
aged ≥12 years, and how this might change following the intro-
duction of ELEX/TEZ/IVA. In previous work we have forecasted 
Table 4 Estimated population means for each outcome in 1 year following the 2018 visit, presented as N/1000 (95% prediction interval (95% PI)), 
and % reductions: with no treatment effects applied, with the effect of TEZ/IVA imposed and with the effect of ELEX/TEZ/IVA imposed
Eligibility group
No treatment effects With TEZ/IVA effect applied to eligible individuals
With ELEX/TEZ/IVA effect applied to eligible 
individuals, including those assumed to 
switch from TEZ/IVA
Mean (95% PI) Mean (95% PI) % reduction (95% PI) Mean (95% PI)
% reduction 
(95% PI)
(A) Using approach 1 for imposing treatment effects
Hospital- IV- days
  Full cohort* 10.6 (10.1, 11.1) 10.1 (9.6, 10.6) 4.8 (–1.2, 10.1) 8.0 (7.6, 8.5) 20.0 (14.3, 25.2)
  TEZ/IVA+ELEX/TEZ/IVA† 11.9 (11.2, 12.8) 11.0 (10.4, 11.7) 7.7 (0.5, 14.4) 8.7 (8.0, 9.4) 20.8 (13.5, 27.4)
  ELEX/TEZ/IVA‡ 11.7 (11.1, 12.3) 11.1 (10.5, 11.7) 5.3 (–0.8, 1.2) 8.5 (8.0, 9.1) 22.7 (16.7, 28.5)
Home- IV- days
  Full cohort 7.4 (7.0, 7.8) 7.2 (6.8, 7.6) 2.5 (–4.2, 8.3) 6.4 (6.1, 6.9) 10.2 (3.7, 16.4)
  TEZ/IVA+ELEX/TEZ/IVA 8.7 (8.1, 9.2) 8.3 (7.7, 9.0) 3.9 (–4.5, 11.7) 7.5 (6.9, 8.1) 10.2 (2.0, 8.1)
  ELEX/TEZ/IVA 8.3 (7.8, 8.8) 8.0 (7.6, 8.6) 2.7 (–4.5, 9.3) 7.1 (6.7, 7.6) 11.4 (4.3, 17.9)
Combined- IV- days
  Full cohort 18.0 (17.3, 18.6) 17.3 (16.7, 17.9) 3.8 (–0.4, 8.0) 14.5 (14.5, 14.5) 16.1 (13.0, 19.2)
  TEZ/IVA+ELEX/TEZ/IVA 20.6 (19.7, 21.6) 19.3 (18.4, 20.3) 6.1 (0.7, 11.4) 16.2 (16.2, 16.2) 16.4 (12.2, 20.3)
  ELEX/TEZ/IVA 20.0 (19.2, 20.8) 19.1 (18.4, 19.9) 4.3 (–0.4, 8.6) 15.7 (15.7, 15.7) 18.1 (14.9, 21.4)
(B) Using approach 2 for imposing treatment effects
Hospital- IV- days
  Full cohort* 10.6 (10.1, 11.1) 8.4 (7.9, 8.8) 21.0 (20.0, 21.9) 4.7 (4.5, 5.0) 43.4 (42.2, 44.6)
  TEZ/IVA+ELEX/TEZ/IVA† 11.9 (11.3, 12.7) 7.8 (7.4, 8.4) 34.3 (33.5, 35.1) 4.5 (4.2, 4.8) 42.6 (41.4, 43.6)
  ELEX/TEZ/IVA‡ 11.7 (11.1, 12.3) 8.9 (8.5, 9.4) 23.7 (22.7, 24.6) 4.4 (4.2, 4.7) 50.6 (49.7, 51.5)
Home- IV- days
  Full cohort 7.4 (7.0, 7.8) 5.8 (5.5, 6.1) 21.8 (20.8, 22.9) 3.2 (3.0, 3.4) 44.0 (42.6, 45.3)
  TEZ/IVA+ELEX/TEZ/IVA 8.7 (8.1, 9.3) 5.7 (5.3, 6.1) 34.3 (33.3, 35.2) 3.3 (3.0, 3.5) 42.6 (41.2, 43.8)
  ELEX/TEZ/IVA 8.3 (7.8, 8.8) 6.3 (5.9, 6.7) 24.2 (23.1, 25.2) 3.1 (2.9, 3.3) 50.2 (49.2, 51.3)
Combined- IV- days
  Full cohort 18.0 (17.3, 18.6) 14.1 (13.6, 14.7) 21.3 (20.6, 22.0) 8.0 (7.6, 8.3) 43.6 (42.7, 44.6)
  TEZ/IVA+ELEX/TEZ/IVA 20.6 (19.7, 21.6) 13.5 (12.9, 14.2) 34.3 (33.6, 34.9) 7.8 (7.4, 8.2) 42.6 (41.7, 43.5)
  ELEX/TEZ/IVA 20.0 (19.2, 20.8) 15.2 (14.6, 15.8) 23.9 (23.1, 24.6) 7.5 (7.2, 7.9) 50.4 (49.7, 51.1)
For the TEZ/IVA effect results, the % reduction is relative to the situation with no treatment effects. For the ELEX/TEZ/IVA results, the % reduction is relative to the TEZ/IVA results.
*The full cohort of n=6407 individuals.
†The subset eligible for both TEZ/IVA and ELEX/TEZ/IVA (n=3481).
‡The whole set of individuals eligible for ELEX/TEZ/IVA, including those assumed to switch from TEZ/IVA (n=5155).
ELEX, elexacaftor; IVA, ivacaft; TEZ, tezacaftor.
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future patient numbers,12 which highlighted the need to plan for 
a larger adult CF population. This study increases our under-
standing of the future needs of this population and illustrates 
how combining registry and RCT data can enable estimation of 
population level treatment impacts.
A key strength of our study is the use of the UK CF Registry, 
which has almost complete coverage of the UK population. Our 
prediction models for hospital- IV- days and home- IV- days were 
well calibrated and produced unbiased internally valid predic-
tions. We evaluated two approaches to imposing the potential 
impacts of TEZ/IVA and ELEX/TEZ/IVA based on primary and 
secondary RCT outcomes, and estimated that the introduction 
of ELEX/TEZ/IVA is expected to result in a significant reduction 
in the total population requirement for IV antibiotics (combined- 
IV- days) of 16.1% using approach 1 (from ~110 600 to~92 800 
days) and 43.6% using approach 2 (from ~90 500 to~43 600 
days). These reductions were in addition to estimated benefits 
derived from starting TEZ/IVA within its licenced indication.
The advantage of approach 1 is that it is based on primary 
outcome RCT data. It assumes that the treatment effects on IV 
antibiotic days are mediated entirely through their effect on 
FEV1%, and that our model accurately captures these causal 
effects through adjustments for potential confounders. When 
considering what predictor variables to include in the model, we 
had to consider the fact that we then wanted to use the model to 
obtain predictions under modified values for FEV1%. Therefore, 
our considerations for the predictor variables to include were 
different from a standard prediction context (where the sole 
aim is to achieve good predictive performance)—we needed the 
coefficient for FEV1% in the prediction model to have a causal 
interpretation in order to apply approach 1. This approach 
might underestimate the effect of ELEX/TEZ/IVA on IV anti-
biotic days if the treatment has effects on reducing IV antibiotic 
days that are not mediated directly via FEV1%, or that are not 
captured by considering FEV1% measured on a single occasion. 
While we adjusted for past FEV1%, on the basis that it is likely to 
Table 5 Predicted number of hospital and home IV antibiotic days in the next year for example patients
(A) Sets of patient characteristics A, B, C. All are aged 30 and female.
Predictor A B C
FEV1% 40 60 80
FEV1% previous year 40 60 80
Body mass index 20 22 25
Pseudomonas aeruginosa Yes Yes No
Staphylococcus aureus Yes Yes No
Burkholderia cepacia Yes Yes No
CF- related diabetes Yes Yes No
Hospital- IV- days, past year 28 14 0
Home- IV- days, past year 28 14 0
(B) Predicted number of hospital and home IV antibiotic days in the next year for nine example patients under no treatment effects, and imposing the effects of TEZ/IVA and 
ELEX/TEZ/IVA using approaches 1 and 2. Each set of characteristics A, B, C is considered in combination with each genotype category (1), (2), (3).
Genotype (1): F508del homoz (eligible 
for TEZ/IVA and ELEX/TEZ/IVA)
Genotype (2): F508del heteroz +minimal (eligible 















Hospital- IV- days   
Approach 1 A 34.2 31.8 25.3 34.6 – 25.6 28.6 – –
  B 14.5 13.4 10.5 14.7 – 10.6 11.0 – –
  C 1.8 1.6 1.2 1.8 – 1.2 1.2 – –
Approach 2 A 34.2 22.2 12.7 34.6 – 12.8 28.6 – –
  B 14.5 9.4 5.4 14.7 – 5.4 11.0 – –
  C 1.8 1.2 0.7 1.8 – 0.7 1.2 – –
Home- IV- days   
Approach 1 A 25.2 24.1 21.1 24.0 – 20.1 18.1 – –
  B 13.2 12.7 11.4 12.5 – 10.7 8.7 – –
  C 5.2 5.1 4.7 4.9 – 4.4 3.2 – –
Approach 2 A 25.2 16.4 9.3 24.0 – 8.9 18.1 – –
  B 13.2 8.6 4.9 12.5 – 4.6 8.7 – –
  C 5.2 3.4 1.9 4.9 – 1.8 3.2 – –
Values of model predictors were chosen for nine example patients defined by three sets of patient characteristics (A, B, C), each combined with three different genotypes: (1) F508del homozygous 
(eligible for TEZ/IVA and ELEX/TEZ/IVA), (2) F508del heterozygous with a minimal function mutation (eligible for ELEX/TEZ/IVA only), (3) any gating mutation (assumed to be using ivacaftor, but not 
eligible for TEZ/IVA or ELEX/TEZ/IVA).
*With TEZ/IVA effect applied to eligible individuals.
†With ELEX/TEZ/IVA effect applied to eligible individuals, including those assumed to switch from TEZ/IVA.
ELEX, elexacaftor; IVA, ivacaftor; TEZ, tezacaftor.
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be a confounder, the high correlation between past and baseline 
FEV1% could also have resulted in the baseline FEV1% effect 
being underestimated. Increased understanding of the mecha-
nisms through which CFTR modulators impact on pulmonary 
exacerbation rates would provide information about as yet 
incompletely understood wider treatment benefits that might 
positively impact on needs for IV antibiotics, and would enable 
further refinements to be made to our projections. Secondary 
analyses of RCT data could be used to investigate the extent 
to which the effect of treatment on exacerbations is mediated 
through its effect on FEV1%.
Approach 2 imposes treatment effects based on secondary RCT 
outcomes assuming that the rate ratio for the treatment effect 
on pulmonary exacerbations can be applied to rates of hospital- 
IV- days and home- IV- days. This assumes that each exacerbation 
results in approximately the same number of hospital- IV- days 
and home- IV- days. The RCT of Taylor- Cousar et al7 considered 
exacerbations that led to hospitalisation or treatment with IV 
antibiotics, and the RCT of Middleton et al considered all exac-
erbations, and also looked separately at those resulting in hospi-
talisation and those requiring treatment with IV antibiotics—in 
this study, we used their results for all exacerbations. The rate 
ratios for exacerbations requiring treatment with antibiotics 
were even lower, suggesting that the impact on hospital- IV- days 
could be even greater than we have projected. A limitation of our 
approach is that there is no RCT evidence on the exacerbation 
rate ratio for ELEX/TEZ/IVA versus TEZ/IVA, which may have 
resulted in an overestimation of the ELEX/TEZ/IVA impact using 
this approach. For approach 2, the estimate of the population 
total number of IV antibiotic days before imposing treatment 
effects could have been taken from an observed population total 
(which does not require knowledge of any covariates), rather 
than estimating the total from a prediction model. However, we 
did not observe population total numbers of IV antibiotic days 
for 2018 (because these data are obtained retrospectively each 
year), and therefore preferred to use the prediction model to 
estimate the baseline population totals. This ensures consistency 
between approaches 1 and 2 in terms of the baseline population 
totals before the treatment effects are imposed.
Study limitations included not having outcome data between 
date of last visit and date of death for some individuals (~4%). 
Requirements for IV antibiotics may be increased in the months 
prior to death which might have resulted in a slight underesti-
mate of population totals. Data from RCTs were restricted to 
pwCF with FEV1% between 40 and 90, whereas we considered 
the entire CF population and did not consider whether there 
could be differences in efficacy among those outside of these 
lung function parameters. Furthermore, the range of mutations 
eligible for access to ELEX/TEZ/IVA is broader than in the 
RCTs. Although recent data suggest a high rate of adherence to 
CFTR modulator treatment, decreasing adherence in the long 
term, outside of RCTs, might negatively impact on the efficacy of 
CFTR modulator treatment in real- world settings.13
As ELEX/TEZ/IVA has begun to be prescribed across the UK, 
the UK CF Registry is collecting follow- up data for all consenting 
pwCF prescribed this treatment. Over time, predicted outcomes 
from our models can be compared with real- world findings. It 
may be difficult to use real- world data for 2020 and 2021 to 
establish the impact of modulator therapies on IV antibiotic use 
as COVID-19 has reshaped the CF landscape with a short- term 
and variable reduction in overall need for antibiotics, probably 
as a result of decreased rates of transmissible infections during 
shielding. The long- term impacts of COVID-19 on CF care are 
unknown but are unlikely to significantly impact on long- term 
need for IV antibiotics. The benefits of ELEX/TEZ/IVA at a CF 
population level are likely to be greater in the future given the 
potential to extend its use to post- transplant, younger age groups 
and a wider range of CF genotypes. It would be of interest to 
perform similar analyses to predict the impact of ivacaftor on 
the same outcomes, using historical Registry data from before 
its introduction combined with RCT data. Projections from this 
modelling could be compared with real- world outcomes after 
the introduction of ivacaftor. This will enable evaluation of the 
accuracy of our predictions and provide further evidence for the 
validity of using Registry data combined with RCTs for health-
care planning.
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